# Liposomal Irinotecan Based FOLFIRI With Bevacizumab in First-line Treatment of Advanced Colorectal Cancer

> **NCT05969899** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Fudan University** · enrollment: 50 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** FOLFIRI+Bevacizumab

## Key facts

- **NCT ID:** NCT05969899
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-07-10
- **Primary completion:** 2025-07-10
- **Final completion:** 2027-02-10
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05969899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05969899, "Liposomal Irinotecan Based FOLFIRI With Bevacizumab in First-line Treatment of Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05969899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*